See more : Truxton Corporation (TRUX) Income Statement Analysis – Financial Results
Complete financial analysis of Graf Acquisition Corp. IV (GFOR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Graf Acquisition Corp. IV, a leading company in the Shell Companies industry within the Financial Services sector.
- China Jicheng Holdings Limited (1027.HK) Income Statement Analysis – Financial Results
- PTT Exploration and Production Public Company Limited (PTTEP-R.BK) Income Statement Analysis – Financial Results
- Zimtu Capital Corp. (ZTMUF) Income Statement Analysis – Financial Results
- Fideicomiso Irrevocable F/2061 FHipo (BNZIF) Income Statement Analysis – Financial Results
- Mobile Streams Plc (MOS.L) Income Statement Analysis – Financial Results
Graf Acquisition Corp. IV (GFOR)
About Graf Acquisition Corp. IV
Graf Acquisition Corp. IV does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2021 and is based in The Woodlands, Texas.
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 25, 2023
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 20, 2023
Graf Acquisition Corp. IV Announces Adjournment of Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 13, 2023
Graf Acquisition Corp. IV Announces Intent to Adjourn Special Meeting to Approve Business Combination with NKGen Biotech, Inc. to September 8, 2023
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical Trial of SNK02, Allogeneic NK Cell Therapy Product Candidate, for the Treatment of Solid Tumors
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Effectiveness of Form S-4 for Proposed Business Combination
Graf Acquisition Corp. IV Currently Has Proxies from More Than 65% of its Stockholders to Approve Extension
Graf Acquisition Corp. IV and NKGen Biotech, Inc. Announce Letter of Intent for a Business Combination
Graf Acquisition Corp. IV Withdraws Extension Proposal
Graf Acquisition Corp. IV Announces the Separate Trading of its Common Stock and Warrants, Commencing July 12, 2021
Source: https://incomestatements.info
Category: Stock Reports